Share on StockTwits

Chimerix (NASDAQ:CMRX) Insider M Michelle Berrey purchased 14,065 shares of Chimerix stock on the open market in a transaction dated Tuesday, May 27th. The stock was purchased at an average price of $14.22 per share, with a total value of $200,004.30. Following the completion of the acquisition, the insider now directly owns 83,271 shares in the company, valued at approximately $1,184,114. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Chimerix (NASDAQ:CMRX) traded up 10.02% during mid-day trading on Wednesday, hitting $19.65. 407,165 shares of the company’s stock traded hands. Chimerix has a 52 week low of $12.96 and a 52 week high of $27.69. The stock’s 50-day moving average is $18. and its 200-day moving average is $18.48. The company’s market cap is $529.9 million.

Chimerix (NASDAQ:CMRX) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.39) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.36) by $0.03. The company had revenue of $0.78 million for the quarter, compared to the consensus estimate of $0.85 million. During the same quarter last year, the company posted ($22.58) earnings per share. Analysts expect that Chimerix will post $-1.83 EPS for the current fiscal year.

A number of research firms have recently commented on CMRX. Analysts at Stifel Nicolaus initiated coverage on shares of Chimerix in a research note on Thursday, March 13th. They set a “buy” rating and a $34.00 price target on the stock. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of Chimerix in a research note on Wednesday, March 12th. They now have a $34.00 price target on the stock.

Chimerix, Inc is a biopharmaceutical company committed to the discovery, development and commercialization of novel, oral antiviral therapeutics that are designed to transform patient care in areas of high unmet medical need.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.